论文部分内容阅读
目的探讨匹多莫德口服液预防过敏性紫癜(HSP)复发的临床疗效。方法选取2010年2月—2014年4月攀枝花市中心医院收治的HSP患儿180例,采用随机数字表法将其分为对照组与观察组,各90例。对照组患儿予以基础治疗,观察组患儿在对照组基础上加用匹多莫德口服液治疗。观察两组患儿治疗前、治疗后1、3个月血浆Th1、Th2细胞分数、Th1/Th2及随访3、6个月、1年的复发情况。结果治疗时间与治疗方法有交互作用(P<0.05),组间比较,差异均有统计学意义(P<0.05),时间间比较,差异均有统计学意义(P<0.05),治疗前两组患儿血浆Th1、Th2细胞分数、Th1/Th2比较,差异无统计学意义(P>0.05),治疗后1、3个月观察组患儿血浆Th1细胞分数、Th1/Th2高于对照组,血浆Th2细胞分数低于对照组,差异有统计学意义(P<0.05);随访3、6个月、1年观察组患儿复发率低于对照组,差异有统计学意义(P<0.05)。结论匹多莫德口服液预防HSP复发的临床疗效显著,可提高患儿免疫功能。
Objective To investigate the clinical efficacy of pidotimod oral solution in preventing the recurrence of Henoch-Schonlein purpura (HSP). Methods 180 cases of HSP children admitted in Panzhihua Central Hospital from February 2010 to April 2014 were randomly divided into control group and observation group with 90 cases in each group. Children in the control group were given basic treatment. The children in the observation group were treated with Pidotimod oral solution on the basis of the control group. The plasma levels of Th1 and Th2, Th1 / Th2, and the follow-up of 3, 6 months and 1 year before and after treatment in two groups were observed. Results There was interaction between treatment time and treatment (P <0.05), and there was significant difference between two groups (P <0.05). The difference was statistically significant (P <0.05) There was no significant difference in the Th1 and Th2 cell scores between the two groups (P> 0.05). Th1 / Th2 was higher in the observation group than in the control group at 1 and 3 months after treatment, The plasma Th2 cell score was lower than that of the control group (P <0.05). The recurrence rate of the 1-year observation group was lower than that of the control group at 3 and 6 months of follow-up (P <0.05) . Conclusion Pidotimod oral solution to prevent the recurrence of HSP significant clinical efficacy, can improve children’s immune function.